EGFR/IGF1R Signaling Modulates Relaxation in Hypertrophic Cardiomyopathy

Standard

EGFR/IGF1R Signaling Modulates Relaxation in Hypertrophic Cardiomyopathy. / Algül, Sila; Schuldt, Maike; Manders, Emmy; Jansen, Valentijn; Schlossarek, Saskia; de Goeij-de Haas, Richard; Henneman, Alex A; Piersma, Sander R; Jimenez, Connie R; Michels, Michelle; Carrier, Lucie; Helmes, Michiel; van der Velden, Jolanda; Kuster, Diederik W D.

In: CIRC RES, Vol. 133, No. 5, 18.08.2023, p. 387-399.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Algül, S, Schuldt, M, Manders, E, Jansen, V, Schlossarek, S, de Goeij-de Haas, R, Henneman, AA, Piersma, SR, Jimenez, CR, Michels, M, Carrier, L, Helmes, M, van der Velden, J & Kuster, DWD 2023, 'EGFR/IGF1R Signaling Modulates Relaxation in Hypertrophic Cardiomyopathy', CIRC RES, vol. 133, no. 5, pp. 387-399. https://doi.org/10.1161/CIRCRESAHA.122.322133

APA

Algül, S., Schuldt, M., Manders, E., Jansen, V., Schlossarek, S., de Goeij-de Haas, R., Henneman, A. A., Piersma, S. R., Jimenez, C. R., Michels, M., Carrier, L., Helmes, M., van der Velden, J., & Kuster, D. W. D. (2023). EGFR/IGF1R Signaling Modulates Relaxation in Hypertrophic Cardiomyopathy. CIRC RES, 133(5), 387-399. https://doi.org/10.1161/CIRCRESAHA.122.322133

Vancouver

Algül S, Schuldt M, Manders E, Jansen V, Schlossarek S, de Goeij-de Haas R et al. EGFR/IGF1R Signaling Modulates Relaxation in Hypertrophic Cardiomyopathy. CIRC RES. 2023 Aug 18;133(5):387-399. https://doi.org/10.1161/CIRCRESAHA.122.322133

Bibtex

@article{2e7fa177d1dc4917a45a05028b7c781d,
title = "EGFR/IGF1R Signaling Modulates Relaxation in Hypertrophic Cardiomyopathy",
abstract = "BACKGROUND: Diastolic dysfunction is central to diseases such as heart failure with preserved ejection fraction and hypertrophic cardiomyopathy (HCM). However, therapies that improve cardiac relaxation are scarce, partly due to a limited understanding of modulators of cardiomyocyte relaxation. We hypothesized that cardiac relaxation is regulated by multiple unidentified proteins and that dysregulation of kinases contributes to impaired relaxation in patients with HCM.METHODS: We optimized and increased the throughput of unloaded shortening measurements and screened a kinase inhibitor library in isolated adult cardiomyocytes from wild-type mice. One hundred fifty-seven kinase inhibitors were screened. To assess which kinases are dysregulated in patients with HCM and could contribute to impaired relaxation, we performed a tyrosine and global phosphoproteomics screen and integrative inferred kinase activity analysis using HCM patient myocardium. Identified hits from these 2 data sets were validated in cardiomyocytes from a homozygous MYBPC3c.2373insG HCM mouse model.RESULTS: Screening of 157 kinase inhibitors in wild-type (n=33) cardiomyocytes (n=24 563) resulted in the identification of 17 positive inotropes and 21 positive lusitropes, almost all of them novel. The positive lusitropes formed 3 clusters: cell cycle, EGFR (epidermal growth factor receptor)/IGF1R (insulin-like growth factor 1 receptor), and a small Akt (α-serine/threonine protein kinase) signaling cluster. By performing phosphoproteomic profiling of HCM patient myocardium (n=24 HCM and n=8 donors), we demonstrated increased activation of 6 of 8 proteins from the EGFR/IGFR1 cluster in HCM. We validated compounds from this cluster in mouse HCM (n=12) cardiomyocytes (n=2023). Three compounds from this cluster were able to improve relaxation in HCM cardiomyocytes.CONCLUSIONS: We showed the feasibility of screening for functional modulators of cardiomyocyte relaxation and contraction, parameters that we observed to be modulated by kinases involved in EGFR/IGF1R, Akt, cell cycle signaling, and FoxO (forkhead box class O) signaling, respectively. Integrating the screening data with phosphoproteomics analysis in HCM patient tissue indicated that inhibition of EGFR/IGF1R signaling is a promising target for treating impaired relaxation in HCM.",
author = "Sila Alg{\"u}l and Maike Schuldt and Emmy Manders and Valentijn Jansen and Saskia Schlossarek and {de Goeij-de Haas}, Richard and Henneman, {Alex A} and Piersma, {Sander R} and Jimenez, {Connie R} and Michelle Michels and Lucie Carrier and Michiel Helmes and {van der Velden}, Jolanda and Kuster, {Diederik W D}",
year = "2023",
month = aug,
day = "18",
doi = "10.1161/CIRCRESAHA.122.322133",
language = "English",
volume = "133",
pages = "387--399",
journal = "CIRC RES",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

RIS

TY - JOUR

T1 - EGFR/IGF1R Signaling Modulates Relaxation in Hypertrophic Cardiomyopathy

AU - Algül, Sila

AU - Schuldt, Maike

AU - Manders, Emmy

AU - Jansen, Valentijn

AU - Schlossarek, Saskia

AU - de Goeij-de Haas, Richard

AU - Henneman, Alex A

AU - Piersma, Sander R

AU - Jimenez, Connie R

AU - Michels, Michelle

AU - Carrier, Lucie

AU - Helmes, Michiel

AU - van der Velden, Jolanda

AU - Kuster, Diederik W D

PY - 2023/8/18

Y1 - 2023/8/18

N2 - BACKGROUND: Diastolic dysfunction is central to diseases such as heart failure with preserved ejection fraction and hypertrophic cardiomyopathy (HCM). However, therapies that improve cardiac relaxation are scarce, partly due to a limited understanding of modulators of cardiomyocyte relaxation. We hypothesized that cardiac relaxation is regulated by multiple unidentified proteins and that dysregulation of kinases contributes to impaired relaxation in patients with HCM.METHODS: We optimized and increased the throughput of unloaded shortening measurements and screened a kinase inhibitor library in isolated adult cardiomyocytes from wild-type mice. One hundred fifty-seven kinase inhibitors were screened. To assess which kinases are dysregulated in patients with HCM and could contribute to impaired relaxation, we performed a tyrosine and global phosphoproteomics screen and integrative inferred kinase activity analysis using HCM patient myocardium. Identified hits from these 2 data sets were validated in cardiomyocytes from a homozygous MYBPC3c.2373insG HCM mouse model.RESULTS: Screening of 157 kinase inhibitors in wild-type (n=33) cardiomyocytes (n=24 563) resulted in the identification of 17 positive inotropes and 21 positive lusitropes, almost all of them novel. The positive lusitropes formed 3 clusters: cell cycle, EGFR (epidermal growth factor receptor)/IGF1R (insulin-like growth factor 1 receptor), and a small Akt (α-serine/threonine protein kinase) signaling cluster. By performing phosphoproteomic profiling of HCM patient myocardium (n=24 HCM and n=8 donors), we demonstrated increased activation of 6 of 8 proteins from the EGFR/IGFR1 cluster in HCM. We validated compounds from this cluster in mouse HCM (n=12) cardiomyocytes (n=2023). Three compounds from this cluster were able to improve relaxation in HCM cardiomyocytes.CONCLUSIONS: We showed the feasibility of screening for functional modulators of cardiomyocyte relaxation and contraction, parameters that we observed to be modulated by kinases involved in EGFR/IGF1R, Akt, cell cycle signaling, and FoxO (forkhead box class O) signaling, respectively. Integrating the screening data with phosphoproteomics analysis in HCM patient tissue indicated that inhibition of EGFR/IGF1R signaling is a promising target for treating impaired relaxation in HCM.

AB - BACKGROUND: Diastolic dysfunction is central to diseases such as heart failure with preserved ejection fraction and hypertrophic cardiomyopathy (HCM). However, therapies that improve cardiac relaxation are scarce, partly due to a limited understanding of modulators of cardiomyocyte relaxation. We hypothesized that cardiac relaxation is regulated by multiple unidentified proteins and that dysregulation of kinases contributes to impaired relaxation in patients with HCM.METHODS: We optimized and increased the throughput of unloaded shortening measurements and screened a kinase inhibitor library in isolated adult cardiomyocytes from wild-type mice. One hundred fifty-seven kinase inhibitors were screened. To assess which kinases are dysregulated in patients with HCM and could contribute to impaired relaxation, we performed a tyrosine and global phosphoproteomics screen and integrative inferred kinase activity analysis using HCM patient myocardium. Identified hits from these 2 data sets were validated in cardiomyocytes from a homozygous MYBPC3c.2373insG HCM mouse model.RESULTS: Screening of 157 kinase inhibitors in wild-type (n=33) cardiomyocytes (n=24 563) resulted in the identification of 17 positive inotropes and 21 positive lusitropes, almost all of them novel. The positive lusitropes formed 3 clusters: cell cycle, EGFR (epidermal growth factor receptor)/IGF1R (insulin-like growth factor 1 receptor), and a small Akt (α-serine/threonine protein kinase) signaling cluster. By performing phosphoproteomic profiling of HCM patient myocardium (n=24 HCM and n=8 donors), we demonstrated increased activation of 6 of 8 proteins from the EGFR/IGFR1 cluster in HCM. We validated compounds from this cluster in mouse HCM (n=12) cardiomyocytes (n=2023). Three compounds from this cluster were able to improve relaxation in HCM cardiomyocytes.CONCLUSIONS: We showed the feasibility of screening for functional modulators of cardiomyocyte relaxation and contraction, parameters that we observed to be modulated by kinases involved in EGFR/IGF1R, Akt, cell cycle signaling, and FoxO (forkhead box class O) signaling, respectively. Integrating the screening data with phosphoproteomics analysis in HCM patient tissue indicated that inhibition of EGFR/IGF1R signaling is a promising target for treating impaired relaxation in HCM.

U2 - 10.1161/CIRCRESAHA.122.322133

DO - 10.1161/CIRCRESAHA.122.322133

M3 - SCORING: Journal article

C2 - 37477020

VL - 133

SP - 387

EP - 399

JO - CIRC RES

JF - CIRC RES

SN - 0009-7330

IS - 5

ER -